Total reported deaths last January were 29. There were 16 fatalities in February, 12 in March, 3 in April, 6 in May, 2 in ...

But the motion was denied due to Fields' refusal to receive the Pfizer-BioNTech vaccine, which Urbanski wrote in ... who ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... A Kaiser Family Foundation survey from 2022 ...

Moderna's Spikevax COVID vaccine brought in sales of $1.8 billion, up 3.5% over the previous year and handily beating analysts' average expectations of $1.38 billion. The company said it benefited ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

In a related JAMA Viewpoint, the authors noted that COVID-19 peaked in 2020 and 2021 as the third highest cause of mortality ...

Regarding the 2024-2025 Pfizer-BioNTech COVID-19 vaccine ... The lawmaker has served in the Senate since 2011 and was most ...

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.

For example, citing a 2022 paper published in Nature Cardiovascular Research ... The Qatar study, for example, estimated the ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...

A 2022 study revealed that 54.5% of people with MS experienced at least one side effect after receiving a third dose of the Pfizer-BioNTech COVID-19 vaccine. The most common side effects they reported ...